Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.070
+0.180 (4.63%)
At close: May 12, 2025, 4:00 PM
4.070
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Y-mAbs Therapeutics Employees
Y-mAbs Therapeutics had 104 employees as of December 31, 2024. The number of employees increased by 4 or 4.00% compared to the previous year.
Employees
104
Change (1Y)
4
Growth (1Y)
4.00%
Revenue / Employee
$843,125
Profits / Employee
-$285,250
Market Cap
184.04M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
YMAB News
- 5 days ago - Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) - GlobeNewsWire
- 6 days ago - Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - GlobeNewsWire
- 15 days ago - Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 17 days ago - Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma - GlobeNewsWire
- 4 weeks ago - Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity - Seeking Alpha
- 2 months ago - Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 2 months ago - Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications - GlobeNewsWire